Zymeworks Inc. (ZYME) surged after positive Phase 3 results for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma, expanding its FDA-approved indications. ZYME's partnership-driven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback